Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs Methylprednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 15 Oct 2018 New trial record
- 12 Oct 2018 Planned End Date changed from 30 Sep 2021 to 31 Oct 2021.
- 12 Oct 2018 Planned primary completion date changed from 30 Sep 2021 to 31 Oct 2021.